{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:17:25Z","timestamp":1791307045133,"version":"4.3.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T00:00:00Z","timestamp":1210291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The objective of this study was to test cladribine (2\u2010CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients with MCL were treated on 2 sequential trials. In Trial 95\u201080\u201053, patients received 2\u2010CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2\u2010CDA and rituximab as initial therapy. In both trials, 2\u2010CDA was administered at a dose of 5 mg\/m<jats:sup>2<\/jats:sup> intravenously on Days 1 through 5 every 4 weeks for 2 to 6 cycles, depending on response. In Trial N0189, rituximab 375 mg\/m<jats:sup>2<\/jats:sup> was administered on Day 1 of each cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Results were reported for 80 patients. Twenty\u2010six previously untreated patients and 25 patients who had recurrent disease with a median age of 68 years received single\u2010agent 2\u2010CDA. The overall response rate (ORR) was 81% with 42% complete responses (CRs) in the previously untreated group. The median progression\u2010free survival (PFS) was 13.6 months (95% confidence interval [95% CI], 7.2\u201022.1 months), and 81% of patients remained alive at 2 years. The ORR was 46% with a 21% CR rate in the recurrent disease group. The median PFS was 5.4 months (95% CI, 4.6\u201013.1 months), and 36% of patients remained alive at 2 years. Twenty\u2010nine eligible patients with a median age of 70 years received 2\u2010CDA plus rituximab. The ORR was 66% (19 of 29 patient), and the CR rate was 52% (15 of 29 patients). The median duration of response for patients who achieved a CR had not been reached at the time of the current report, and only 3 of the patients who achieved a CR developed recurrent disease at a median follow\u2010up of 21.5 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>2\u2010CDA had substantial single\u2010agent activity in both recurrent and untreated MCL, and the results indicated that it may be administered safely to elderly patients. The addition of rituximab to 2\u2010CDA may increase the duration of response. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23537","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T15:16:25Z","timestamp":1210346185000},"page":"108-116","source":"Crossref","is-referenced-by-count":57,"title":["Long\u2010term results of the treatment of patients with mantle cell lymphoma with cladribine (2\u2010CDA) alone (95\u201080\u201053) or 2\u2010CDA and rituximab (N0189) in the North Central Cancer Treatment Group"],"prefix":"10.1002","volume":"113","author":[{"given":"David J.","family":"Inwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. S.","family":"Fishkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe F.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Veeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj992"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.017"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04761.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199811000-00011"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.3.319"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0193-2"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531951"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"issue":"14","key":"e_1_2_5_16_2","article-title":"Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"22","author":"Hiddemann W","year":"2004","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0858-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl127"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909145712"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00143-0"},{"key":"e_1_2_5_22_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22196"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.114207"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200391"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705357"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200061"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl348"},{"key":"e_1_2_5_35_2","first-page":"104","article-title":"A Phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)","author":"Oki Y","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1215"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.5.3.477"},{"key":"e_1_2_5_44_2","first-page":"108","article-title":"Preliminary results from a phase II study of lenalidomide monotherapy in relapsed\/refractory aggressive non\u2010Hodgkins lymphoma","author":"Wiernik PH","year":"2006","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23537","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:39:06Z","timestamp":1760305146000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1002\/cncr.23537"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23537","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,20]]}}}